Elevated PGC-1α activity sustains mitochondrial biogenesis and muscle function without extending survival in a mouse model of inherited ALS - PubMed (original) (raw)

. 2012 May 2;15(5):778-86.

doi: 10.1016/j.cmet.2012.03.019.

Philippe A Parone, Vanda S Lopes, Concepción Lillo, Melissa McAlonis-Downes, Sandra K Lee, Anne P Vetto, Susanna Petrosyan, Martin Marsala, Anne N Murphy, David S Williams, Bruce M Spiegelman, Don W Cleveland

Affiliations

Elevated PGC-1α activity sustains mitochondrial biogenesis and muscle function without extending survival in a mouse model of inherited ALS

Sandrine Da Cruz et al. Cell Metab. 2012.

Abstract

The transcriptional coactivator PGC-1α induces multiple effects on muscle, including increased mitochondrial mass and activity. Amyotrophic lateral sclerosis (ALS) is a progressive, fatal, adult-onset neurodegenerative disorder characterized by selective loss of motor neurons and skeletal muscle degeneration. An early event is thought to be denervation-induced muscle atrophy accompanied by alterations in mitochondrial activity and morphology within muscle. We now report that elevation of PGC-1α levels in muscles of mice that develop fatal paralysis from an ALS-causing SOD1 mutant elevates PGC-1α-dependent pathways throughout disease course. Mitochondrial biogenesis and activity are maintained through end-stage disease, accompanied by retention of muscle function, delayed muscle atrophy, and significantly improved muscle endurance even at late disease stages. However, survival was not extended. Therefore, muscle is not a primary target of mutant SOD1-mediated toxicity, but drugs increasing PGC-1α activity in muscle represent an attractive therapy for maintaining muscle function during progression of ALS.

Copyright © 2012 Elsevier Inc. All rights reserved.

PubMed Disclaimer

Figures

Figure 1

Figure 1. Elevating PGC-1α Expression Activates Known PGC-1α Responsive Pathways, Including Mitochondrial Biogenesis in Skeletal Muscles of SOD1G37R Mutant Mice throughout Disease

(A) Relative mRNA expression levels were determined by quantitative real-time PCR for VEGF, catalase, and SOD2 in gastrocnemius isolated from SOD1G37R and SOD1G37R/MCK-PGC-1α animals throughout disease. Data are presented as mean ± SEM. See also Figure S1. (B) Relative numbers of acetylcholine receptor (AChR) clusters per section of gastrocnemius were determined by staining with α-bungarotoxin. Data are presented as mean ± SEM. (C) Electron micrographs from cross-sections taken from tibialis anterior muscle of SOD1G37R and SOD1G37R/MCK-PGC-1α animals at asymptomatic (4 months) and end-stage of disease (13–14 months). Scale bar = 0.5 µm. (D) Total area of mitochondria per 20 µm2 of myofiber from tibialis anterior muscle of SOD1G37R and SOD1G37R/MCK-PGC-1α animals at asymptomatic (4 months), symptomatic (12 months), and end-stage of disease (13–14 months). Data are presented as mean ± SEM.

Figure 2

Figure 2. Elevating PGC-1α Expression Improves Muscle Activity and Locomotive Activity in Mutant SOD1G37R Mice

(A) Fatigue index of hindlimb muscles from SOD1G37R and SOD1G37R/MCK-PGC-1α animals throughout disease. Fatigue index was quantified as the period (in seconds) of high-frequency electrical stimulation required to obtain a 50% decrease in muscle contraction. Data are presented as mean ± SEM. See also Figure S2. (B) Treadmill performance (total distance and run time on the treadmill determined until exhaustion) of SOD1G37R and SOD1G37R/MCK-PGC-1α animals at the symptomatic stage of disease. Data are presented as mean ± SEM. (C) Running wheel performance of SOD1G37R and SOD1G37R/MCK-PGC-1α animals at the symptomatic stage of disease. Total distance and run time on the wheel were determined during a 5 min testing period. Average speed corresponds to the mean speed of running during the mobile period. Data are presented as mean ± SEM. (D) Open field performance of SOD1G37R and SOD1G37R/MCK-PGC-1α animals at the symptomatic stage of disease. Total distance covered and the time mobile were determined during a 60 min of tracking period. Average speed corresponds to the mean speed of movement during the mobile period. Data are presented as mean ± SEM.

Figure 3

Figure 3. Elevating PGC-1α Expression Reduces Muscle Atrophy and Expression of Muscle Degeneration Genes and Increases Overall Muscle Mitochondrial ADP Phosphorylation Capacity in Mutant SOD1G37R Mice throughout Disease

(A) Representative hematoxylin and eosin stainings of the gastrocnemius muscle in asymptomatic and symptomatic SOD1G37R and SOD1G37R/MCK-PGC-1α animals. The inset indicates clusters of small angular degenerating fibers. (B) Quantification of average fiber area from hematoxylin and eosin-stained gastrocnemius muscle from SOD1G37R and SOD1G37R/MCK-PGC-1α animals throughout disease. Data are presented as mean ± SEM. See also Figure S3. (C) Relative mRNA expression levels of muscular degeneration markers MuRF-1 and cathepsin L in gastrocnemius muscle isolated from asymptomatic and symptomatic mutant SOD1G37R and SOD1G37R/MCK-PGC-1α animals. mRNA expression was evaluated by quantitative real-time PCR. Data are presented as mean ± SEM. (D) Levels of ADP-stimulated mitochondrial oxygen consumption in mitochondria isolated from the gastrocnemius muscle of symptomatic mutant SOD1G37R and SOD1G37R/MCK-PGC-1α and age-matched nontransgenic and MCK-PGC-1α animals oxidizing pyruvate and malate. In coupled mitochondrial respiration, oxygen consumption is directly proportional to the amount of ATP synthesized. Data are presented as mean ± SEM.

Figure 4

Figure 4. Elevating PGC-1α Expression in Skeletal Muscle of SOD1G37R Mutant Mice Does Not Alter ALS Disease Course or Pathogenesis

(A) Plot of ages (in days) at which disease onset (as determined by the weight peak; at onset, animals do not display any obvious motor phenotype), symptomatic stage (as determined by 10% weight loss from onset, a stage characterized by clear gait abnormalities and tremor) and end-stage (as determined by hindlimb paralysis and inability to right itself) were reached for SOD1G37R (red) and SOD1G37R/MCK-PGC-1α (blue) animals. (B–D) Quantification of innervation at the neuromuscular junction of the gastrocnemius muscle (B), total number of α-motor axons in the lumbar L5 motor root (C), and quantification at disease end-stage of the average number of large cholinergic ventral horn motor neurons per section of lumbar spinal cord from SOD1G37R and SOD1G37R/MCK-PGC-1α animals (D). Data are presented as mean ± SEM. See also Figure S4 for representative sections of the spinal cords used for quantification. (E) Representative micrographs of lumbar spinal cord sections from SOD1G37R and SOD1G37R/MCK-PGC-1α animals at disease end-stage processed for immunofluorescence using antibodies detecting activated astrocytes (GFAP) or microglia (IbaI). Dashed outlines correspond to the boundary between gray and white matter.

Comment in

Similar articles

Cited by

References

    1. Arany Z, Foo SY, Ma Y, Ruas JL, Bommi-Reddy A, Girnun G, Cooper M, Laznik D, Chinsomboon J, Rangwala SM, et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature. 2008;451:1008–1012. - PubMed
    1. Boillée S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, Kollias G, Cleveland DW. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312:1389–1392. - PubMed
    1. Bruijn LI, Houseweart MK, Kato S, Anderson KL, Anderson SD, Ohama E, Reaume AG, Scott RW, Cleveland DW. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science. 1998;281:1851–1854. - PubMed
    1. Chakkalakal JV, Nishimune H, Ruas JL, Spiegelman BM, Sanes JR. Retrograde influence of muscle fibers on their innervation revealed by a novel marker for slow motoneurons. Development. 2010;137:3489–3499. - PMC - PubMed
    1. Damiano M, Starkov AA, Petri S, Kipiani K, Kiaei M, Mattiazzi M, Flint Beal M, Manfredi G. Neural mitochondrial Ca2+ capacity impairment precedes the onset of motor symptoms in G93A Cu/Zn-superoxide dismutase mutant mice. J. Neurochem. 2006;96:1349–1361. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources